Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 105
- Registration Number
- NCT00039130
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 587
- Registration Number
- NCT00006734
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Illinois Medical Center, Chicago, Illinois, United States
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Target Recruit Count
- 27
- Registration Number
- NCT00006373
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 150
- Registration Number
- NCT00001300
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.